'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
'FDA Grants Priority Review Of MDMA-Assisted Therapy For PTSD, Psychedelics Drug Development Company Says' - Marijuana Moment
“迷幻藥藥物開發公司表示，美國食品藥品管理局批准對創傷後應激障礙的****輔助療法進行優先審查”-大麻時刻
The Food and Drug Administration (FDA) has agreed to review MDMA-assisted therapy as a potential treatment option for post-traumatic stress disorder (PTSD), and the application has been granted priority status, according to the psychedelics-focused drug development company that's leading the effort.
領導這項工作的專注於迷幻藥的藥物開發公司表示，美國食品藥品監督管理局（FDA）已同意審查****輔助療法作爲創傷後應激障礙（PTSD）的潛在治療選擇，該申請已獲得優先地位。
About two months after Lykos Therapeutics (formerly MAPS Public Benefit Corporation) submitted the new drug application (NDA) for MDMA in combination with psychotherapy, FDA granted it priority review last week and has set a target date for determination by August 11, the company announced on Friday.
該公司週五宣佈，在Lykos Therapeutics（前身爲MAPS公共福利公司）提交結合心理治療的****新藥申請（NDA）大約兩個月後，美國食品藥品管理局上週批准了其優先審查，並將確定目標日期定爲8月11日。
If the NDA is ultimately approved, the Drug Enforcement Administration...
如果保密協議最終獲得...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。